Corporate Information

Summary

Immutep is a biologics company in the fast-growing field of targeted protein-based immunotherapeutics. The Company is well-advanced in the clinic and is planning a Phase IIb/III trial. It is based near Paris, France.

The Company is developing two complementary types of therapeutic proteins:


• new classes of human protein immunostimulatory factors for the treatment of cancer and chronic infections (ImmuFact® and ImmuCcine®).
• therapeutic antibodies for the modulation of the immune system in cancer, autoimmune diseases and transplantation (ImmuTune®).

Each type of therapeutic is based on newly-discovered pathways involved in the Lymphocyte Activation Gene-3 (LAG-3) immune control mechanism, which plays a vital role in the regulation of the immune system. These pathways were discovered by the Company's scientific founder, Pr. Frédéric Triebel, initially developed in collaboration between the Institut Gustave Roussy and Merck-Serono, and then confirmed by several independent teams.

This has enabled Immutep to build a distinctive platform providing diversified risks and opportunities while maintaining scientific focus.